Clinical Trials · NCT02906150
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- SciClone Pharmaceuticals
- Enrollment
- 140
- Start date
- Sep 2016
- Locations
- 8 sites, Italy
- Primary endpoint
- Time to progression free survival (PFS)